Pii will be responsible for all commercial drug product production and Sagent Pharmaceuticals, the ANDA holder, will sell, market and distribute the drug product in the U.S.

“We are pleased to support Sagent Pharmaceuticals in its efforts to supply an affordable treatment option for post-menopausal patients suffering from breast cancer. Pii’s Pharmaceutics Know-How has once again proven valuable to one of our partners, as they strive to develop and provide approved drug products to patients in need. Fulvestrant Injection 250mg/5ml drug product is the 5th injectable product approved and produced by Pii, during the past two years,” said Dr. Kurt Nielsen, Pii's President and CEO.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!